Sichen Formula Ameliorates Lipopolysaccharide-Induced Acute Lung Injury via Blocking the TLR4 Signaling Pathways
Drug Design, Development and Therapy · 2023
DOI: 10.2147/dddt.s372981 ↗Kurz gefasst
Fachartikel in der Zeitschrift Drug Design, Development and Therapy, 2023. Verfasst von Li-Shan Yan und 8 weiteren Autor:innen. Beteiligte Einrichtung: School of Chinese Materia Medica, Beijing University of Chinese Medicine, Beijing, People's Republic of China. Hauptthemen laut MEDLINE: Acute Lung Injury, Toll-Like Receptor 4. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 36 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 3.0).
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- School of Chinese Materia Medica, Beijing University of Chinese Medicine, Beijing, People's Republic of China.
- College of Professional and Continuing Education, Hong Kong Polytechnic University, Hong Kong, People's Republic of China.
- Tibetan Traditional Medical College, Lhasa, Tibet, People's Republic of China.
ORCID-Profile: Brian Chi-Yan Cheng, Yi Zhang
Zitieren
APA
Yan, L. S., Cui, S., Cheng, B. C., Yin, X. B., Wang, Y. W., Qiu, X. Y., Nima, C. R., Zhang, Y., & Zhang, S. F. (2023). Sichen Formula Ameliorates Lipopolysaccharide-Induced Acute Lung Injury via Blocking the TLR4 Signaling Pathways. Drug Design, Development and Therapy. https://doi.org/10.2147/dddt.s372981
Vancouver
Yan LS, Cui S, Cheng BC, Yin XB, Wang YW, Qiu XY, et al. Sichen Formula Ameliorates Lipopolysaccharide-Induced Acute Lung Injury via Blocking the TLR4 Signaling Pathways. Drug Design, Development and Therapy. 2023. doi:10.2147/dddt.s372981
BibTeX
@article{Yan2023,
author = {Yan, Li-Shan and Cui, Shuang and Cheng, Brian Chi-Yan and Yin, Xing-Bin and Wang, Yi-Wei and Qiu, Xin-Yu and Nima, Ci-Ren and Zhang, Yi and Zhang, Shuo-Feng},
title = {Sichen Formula Ameliorates Lipopolysaccharide-Induced Acute Lung Injury via Blocking the TLR4 Signaling Pathways},
journal = {Drug Design, Development and Therapy},
year = {2023},
doi = {10.2147/dddt.s372981}
}
EUVIMED